GLP-1 Explained
Semaglutide for Weight Loss: What Research Shows
What do the clinical trials actually show for semaglutide in weight management? A Singapore doctor summarises the evidence — results, side effects and maintenance.
Semaglutide is among the most studied molecules in modern weight medicine — which means the honest question is not “does it work?” but “what exactly does the evidence show, for whom, and for how long?” Here is the research, summarised for patients.
The trial programme, in plain numbers
The weight-management formulation of semaglutide was studied in a large international programme (the STEP trials), which compared treatment plus lifestyle counselling against placebo plus counselling:
| Semaglutide + lifestyle | Lifestyle alone | |
|---|---|---|
| Average weight loss | ~15% of body weight | ~2–3% |
| Duration | ~68 weeks | ~68 weeks |
| Diabetes prevention (separate trial) | Substantial reduction in progression | — |
Two honest caveats matter as much as the headline:
- Average hides range. Some participants lost over 20%, others under 5%. Your result depends on your biology, your starting point, adherence and the programme around you.
- Trial conditions flatter every treatment. Participants had regular support, monitoring and coaching — not a prescription handed over and forgotten.
What improves besides weight
The trial data and follow-up studies show improvements that go beyond the scale:
- Blood sugar — improved control in people with type 2 diabetes; reduced progression from pre-diabetes in dedicated trials
- Cardiovascular markers — improvements in blood pressure, lipids and inflammatory markers
- Sleep apnoea — significant improvement in apnoea severity in patients with obesity
- Quality of life — measurable gains in physical function and well-being
This is the “5–10% matters” principle in practice: even before major weight is lost, metabolic health can improve.
Side effects, in proportion
The common effects are digestive — nausea, constipation, diarrhoea — concentrated in the first weeks and during dose increases, and usually settling. A minority experience more troublesome symptoms, and rare but serious complications (pancreatitis, gallbladder disease) are recognised — the reason supervision exists. This is covered in more detail in our GLP-1 side effects guide.
The maintenance finding — the most important part
When treatment stopped in the trials, participants typically regained much of the lost weight over the following year without ongoing support. This is biology, not failure: appetite signals return to their previous set-point. The practical conclusion of the evidence is that obesity is a chronic condition needing a long plan — structured transition and maintenance support are part of the treatment, not an afterthought.
What this means for treatment decisions
- Success is realistic but not guaranteed — roughly 10–15% average losses with support, wide individual variation
- The programme matters as much as the molecule — nutrition, protein, activity, monitoring
- Maintenance is the long game — the trial data says so plainly
- Assessment comes first — semaglutide is prescription-only with specific contraindications; suitability is a clinical decision
If you are considering treatment, bring these numbers to your consultation — a good clinic will discuss the evidence with you honestly rather than promise an outcome. Our weight management programme is built around that conversation, the semaglutide ingredient explainer covers the molecule itself, and the GLP-1 guide covers the class in full.
Frequently asked questions
How effective is semaglutide for weight loss in the trials?
In the major trial programme (the STEP series), participants receiving the weight-management dose alongside lifestyle counselling lost around 15% of body weight on average over roughly 68 weeks, versus about 2–3% with lifestyle alone. Individual results varied widely — some lost far more, some considerably less.
How much of the weight loss is fat versus muscle?
Roughly three-quarters of the weight lost in these trials was fat mass, with around a quarter being lean mass — a pattern consistent with other rapid weight-loss methods. Protein intake and resistance training meaningfully shift that ratio, which is why supervised programmes track body composition.
What happens when semaglutide is stopped?
Appetite signalling returns towards its previous state over weeks, and without a maintenance plan, much of the lost weight is typically regained. The trial data is clear on this — which is why planned transition and maintenance support are part of responsible programmes, not optional extras.
Is semaglutide safe?
For most people who are clinically suitable, the safety profile is well studied, with digestive side effects being the most common and usually settling. It is prescription-only, has specific contraindications, and requires medical assessment and monitoring — this is not a medicine for self-directed use.
